These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21925076)

  • 1. The GH/IGF-1 system in critical illness.
    Elijah IE; Branski LK; Finnerty CC; Herndon DN
    Best Pract Res Clin Endocrinol Metab; 2011 Oct; 25(5):759-67. PubMed ID: 21925076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone and IGF-I therapy in the hypercatabolic patient.
    Wolf SE; Barrow RE; Herndon DN
    Baillieres Clin Endocrinol Metab; 1996 Jul; 10(3):447-63. PubMed ID: 8853450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human growth hormone for treating burns and donor sites.
    Breederveld RS; Tuinebreijer WE
    Cochrane Database Syst Rev; 2012 Dec; 12():CD008990. PubMed ID: 23235668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone, burns and tissue healing.
    Lal SO; Wolf SE; Herndon DN
    Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S39-43. PubMed ID: 10984252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of therapy with recombinant human growth hormone on insulin-like growth factor system components and serum levels of biochemical markers of bone formation in children after severe burn injury.
    Klein GL; Wolf SE; Langman CB; Rosen CJ; Mohan S; Keenan BS; Matin S; Steffen C; Nicolai M; Sailer DE; Herndon DN
    J Clin Endocrinol Metab; 1998 Jan; 83(1):21-4. PubMed ID: 9435411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined insulin-like growth factor-1 and growth hormone improves weight loss and wound healing in burned rats.
    Meyer NA; Barrow RE; Herndon DN
    J Trauma; 1996 Dec; 41(6):1008-12. PubMed ID: 8970554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anabolic agents in trauma and sepsis: repleting body mass and function.
    Saito H
    Nutrition; 1998 Jun; 14(6):554-6. PubMed ID: 9646302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of combined treatment of recombinant human growth hormone and insulin-like growth factor-1 on wound healing and protein catabolism in burned rats].
    Chen HD; Xie JL; Lai W
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 1999 Nov; 13(6):386-9. PubMed ID: 12080844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The growth hormone and insulin-like growth factor axis: its manipulation for the benefit of growth disorders in renal failure.
    Roelfsema V; Clark RG
    J Am Soc Nephrol; 2001 Jun; 12(6):1297-1306. PubMed ID: 11373355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with GH and IGF-1 in critical illness.
    Teng Chung T; Hinds CJ
    Crit Care Clin; 2006 Jan; 22(1):29-40, vi. PubMed ID: 16399018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mecasermin (recombinant human insulin-like growth factor I).
    Rosenbloom AL
    Adv Ther; 2009 Jan; 26(1):40-54. PubMed ID: 19198769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human growth hormone and recombinant human insulin-like growth factor I diminish the catabolic effects of hypogonadism in man: metabolic and molecular effects.
    Hayes VY; Urban RJ; Jiang J; Marcell TJ; Helgeson K; Mauras N
    J Clin Endocrinol Metab; 2001 May; 86(5):2211-9. PubMed ID: 11344229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anabolic strategies in critical illness.
    Hadley JS; Hinds CJ
    Curr Opin Pharmacol; 2002 Dec; 2(6):700-7. PubMed ID: 12482734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic and splanchnic metabolic response to exogenous human growth hormone.
    Dahn MS; Lange MP
    Surgery; 1998 May; 123(5):528-38. PubMed ID: 9591005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human growth hormone plus recombinant human insulin-like growth factor-1 coadministration therapy in short children with low insulin-like growth factor-1 and growth hormone sufficiency: results from a randomized, multicenter, open-label, parallel-group, active treatment-controlled trial.
    Backeljauw PF; Miller BS; Dutailly P; Houchard A; Lawson E; Hale DE; Reiner B; Sperling MA;
    Horm Res Paediatr; 2015; 83(4):268-79. PubMed ID: 25765099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
    Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness.
    Van den Berghe G; Baxter RC; Weekers F; Wouters P; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2000 Jan; 85(1):183-92. PubMed ID: 10634385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altering metabolism.
    Pereira CT; Murphy KD; Herndon DN
    J Burn Care Rehabil; 2005; 26(3):194-9. PubMed ID: 15879740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of insulin-like growth factor-I in skeletal muscle and muscle cells.
    Frost RA; Lang CH
    Minerva Endocrinol; 2003 Mar; 28(1):53-73. PubMed ID: 12621363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of growth hormone therapy in burn patients on conservative treatment.
    Singh KP; Prasad R; Chari PS; Dash RJ
    Burns; 1998 Dec; 24(8):733-8. PubMed ID: 9915674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.